RecruitingPhase 1Phase 2NCT06639347

A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma

An Open Label, Multicenter, Phase Ib/Il Study to Evaluate the Safety, Tolerability, and Efficacy of SHR A2102 in Combination With Other Anti-cancer Agents in Patients With Advanced Urothelial Carcinoma

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrollment

90 participants

Start Date

Nov 4, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Urothelial Carcinoma

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with Antitumor Therapy in Advanced Urothelial Carcinoma. To explore the reasonable dosage of SHR-A2102 for Advanced Urothelial Carcinoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Adebrelimab injection, a drug called SHR-8068 injection, and others for people with advanced urothelial carcinoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.